Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Price: $3.00 --0%
Financial Fact:
Loss from operations: -4.48M
Today's EPS Names:
OCCI, IPX, ALZN, More
Financial Fact:
Loss from operations: -4.48M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.
For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and memory not a classic bubble, but future returns uncertain - strategist
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Voya Financial warns shareholders about unsanctioned TCIM straw poll
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
